Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2015 Apr 1;68(4):e56-9.
doi: 10.1097/QAI.0000000000000504.

No relationship between drug transporter genetic variants and tenofovir plasma concentrations or changes in glomerular filtration rate in HIV-infected adults

Wasna Sirirungsi  1 , Saik Urien, Linda Harrison, Jiraporn Kamkon, Yardpiroon Tawon, Nuananong Luekamlung, Suchart Thongpaen, Ampaipith Nilmanat, Gonzague Jourdain, Marc Lallemant, Sophie Le Coeur, Nicole Ngo-Giang-Huong, Andrew Owen, Tim R Cressey
Affiliations
Observational Study

No relationship between drug transporter genetic variants and tenofovir plasma concentrations or changes in glomerular filtration rate in HIV-infected adults

Wasna Sirirungsi et al. J Acquir Immune Defic Syndr. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Transporter polymorphisms and predicted plasma tenofovir C24 (μg/ml) after 1 and 3 years of treatment. The middle bar indicates the median. Numbers of subjects are indicated below each group. Wilcoxon rank-sum test were used to compare tenofovir C24 between combined variant and homozygosity of the common allele (p-value). Comparisons were adjusted for multiple testing using the method of Benjamini-Hochberg to control for the False Discovery Rate (q-value). Data presented for SNPs with a MAF >0.004.
See this image and copyright information in PMC

References

    1. Rodriguez-Novoa S, Labarga P, Soriano V. Pharmacogenetics of tenofovir treatment. Pharmacogenomics. 2009;10:1675–1685. - PubMed
    1. Yombi JC, Pozniak A, Boffito M, et al. Antiretrovirals and the kidney in current clinical practice: renal pharmacokinetics, alterations of renal function and renal toxicity. AIDS. 2014;28:621–632. - PubMed
    1. Goicoechea M, Zheng Y, Hughes M, et al. Antiretroviral regimen and pharmacogenetic determinants of tenofovir-associated change in creatinine clearance in ACTG protocol A5142.. In. XVIII International AIDS Conference; July 18–32, 2010; Vienna, Austria. 2010. Abstract: WEAB0305.
    1. Poizot-Martin I, Solas C, Allemand J, et al. Renal impairment in patients receiving a tenofovir-cART regimen: Impact of tenofovir trough concentration. J Acquir Immune Defic Syndr. 2012 - PubMed
    1. Manosuthi W, Sukasem C, Thongyen S, Nilkamhang S, Sungkanuparph S. ABCC2*1C and plasma tenofovir concentration are correlated to decreased glomerular filtration rate in patients receiving a tenofovir-containing antiretroviral regimen. J Antimicrob Chemother. 2014 - PubMed

Publication types

MeSH terms